BioNTech SE Q3 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Can you outline what key pipeline updates we should expect between now and year-end? You mentioned an update on the iNest melanoma trial. What else should we be looking forward to whether from the 4-1BB programs or otherwise? And then related to iNest, with the new trial starting in the adjuvant pancreatic cancer, can you talk about what drove that decision? And was it based on something you're seeing? And then lastly, just a financial question. You lowered OpEx guidance again this quarter, but also suggested that from here, R&D will likely grow to support these pipeline investments. What about SG&A? That guidance didn't change as much. Is there less flexibility in that line if expenses need to be cut again?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : And then what about on the new iNest trial in adjuvant pancreatic? Can you talk about what drove the decision to start that up, and SG&A flexibility question.

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : Just in terms of thinking about the profitability of the COVID vaccine business, just how should we think about the Pfizer COVID vaccine gross profit margins going forward just given the endemic market and the impact this has on the revenue you recognize? You mentioned the continued shift to single-dose vials and prefilled syringes. Just trying to think about how you're thinking about long-term potential margins for that business and the impact on the revenues that you'd recognize as part of the profit share.